Showing posts with label Contrarian Investing. Show all posts
Showing posts with label Contrarian Investing. Show all posts

Sunday, April 20, 2025

Buy the Dip: The Draw and Dangers of Contrarian Investing!

     When markets are in free fall, there is a great deal of  advice that is meted out to investors, and one is to just buy the dip, i.e., buy beaten down stocks, in the hope that they will recover, or the entire market, if it is down.  "Buying the dip" falls into a broad group of investment strategies that can be classified as "contrarian", where investors act in contrast to what the rest of the market is doing at the time, buying (selling) when the vast majority are selling (buying) , and it has been around through all of market history. There are strands of research in both behavioral finance and empirical studies that back up contrarian strategies, but as with everything to do with investing, it comes with caveats and constraints. In this post, I will posit that contrarian investing can take different forms, each based on different assumptions about market behavior, and present the evidence that we have on the successes and failures of each one. I will argue that even if you are swayed intellectually by the arguments for going against the crowd, it may not work for you, if you are not psychologically attuned to the stresses and demands that contrarian strategies bring with them.

Contrarianism - The Different Strands

    All contrarian investing is built around a common theme of buying an investment, when its price goes down significantly, but there are wide variations in how it is practiced. In the first, knee-jerk contrarianism, you use a bludgeon, buying either individual companies or the entire market when they are down, on the expectation that you will benefit from an inevitable recovery in prices. In the second, technical contrarianism, you buy beaten-up stocks or the entire market, but only if charting or technical indicators support the decision.  In the third, constrained contrarianism, you buy the stocks that are down, but only if they pass your screens for qualify and safety. In the fourth, opportunistic contrarianism, you use a price markdown as an opportunity to buy companies that you have always wanted to hold, but had not been able to buy because they were priced too high.

1. Knee-jerk Contrarianism

    The simplest and most direct version of contrarian investing is to buy any traded asset where the price is down substantially from its highs, with the asset sometimes being an individual company, sometimes a sector and sometimes the entire market. Implicit in this strategy is an absolute belief in mean reversion, i.e.,  that what goes down will almost always go back up, and that buying at the beaten down price and being willing to wait will therefore pay off.

    The evidence for this strategy comes from many sources. For the market, it is often built on papers (or books) that look at the historical data on what equity markets have delivered as returns over long periods, relative to what you would have made investing elsewhere. Using data for the United States, a  market with the longest and most reliable historical records, you can see the substantial payoff to investing in equities:

Download historical data

No matter what time period you use for your time horizon, stocks deliver the highest returns, of all asset classes, and there some who look at this record and conclude that "stocks always win in the long term", with the implication that you should stay fully invested in stocks, even through the worst downturns, if you have a reasonably long time horizon. These returns to buying stocks become greater, when you buy them when they are cheaper, measured either through pricing metrics (low PE ratios) or after corrections. There are two problems with the conclusion. The first is that there is selection bias, where using historical data from the United States, one of the most successful equity markets of the last century, to draw general conclusions about the risk and returns of investing in equities will lead you to underestimate equity risk and overestimate equity returns. The second is that, even with US equities, an investor who bought stocks just before a major downturn would have to wait a long time before being made whole again. Thus, investors who put their money in stocks in 1929, just ahead of the Great Depression, would not have recovered until 1954. 

    With individual stocks, the strongest backing for buying the dip comes from studies of "loser" stocks, i.e., stocks that have gone down the most over a prior period. In a widely cited paper from 1985, DeBondt and Thaler classified stocks based upon stock price performance in the prior three years into winner and loser portfolios, with the top fifty performers going into the "winner" portfolio, and the bottom fifty into the "losers portfolio", and estimated the returns you could have made on each group in the following thirty six months:

DeBondt and Thaler (1985)

As you can see, the loser portfolio dramatically outperforms the winner portfolio, delivering about 30% more on a cumulative basis than the winner portfolio in the thirty six months after the portfolios are created, which DeBondt and Thaler argued was evidence that markets overreact. About a decade later, Jegadeesh and Titman revisited the study, with more granular data on time horizons, and found that the results were reversed, if you shorten the holding period, with winner stocks continuing to win over the first year after portfolio creation. 

Jegadeesh and Titman (1993)

The reversal eventually kicks in after a year, but over the entire time period, the winner portfolio still outperforms the loser portfolio, on a cumulative basis. Jegadeesh and Titman also noted a skew in the loser portfolio towards smaller market cap and lower-priced stocks, with higher transactions costs (from bid-ask spreads and price impact). As other studies have added to the mix, the consensus on winner versus loser stocks is that there is no consensus, with evidence for both momentum, with winner stocks continuing to win, and for reversal, with loser stocks outperforming, depending on time horizon, and questions about whether these excess returns are large enough to cover the transactions costs involved.

    Setting aside the mixed evidence for the moment, the biggest danger in knee-jerk contrarian investing at the market level is that buying the dip in the market is akin to catching a falling knife, since that initial market drop can be a prelude to a much larger sell off, and to the extent that there was an economic or fundamental reason for the sell off (a banking crisis, a severe recession), there may be no near term bounceback. With individual stocks, that danger gets multiplied, with investors buying stocks that are being sold off to for legitimate reasons (a broken business model, dysfunctional management, financial distress) and waiting for a market correction that never comes. 

    To examine the kinds of companies that you would invest in, with a knee-jerk contrarian investing strategy , I looked at all US stocks with a market capitalization exceeding a billion dollars on December 31, 2024, and found the companies that were the biggest losers, on a percent basis, between March 28 and April 18 of 2025:

You will note that technology and biotechnology firms are disproportionately represented on the list, but that is the by-product of a bludgeon approach.

2. Technical Contrarianism

    In technical contrarianism, you start with the same basis as knee-jerk contrarianism, by  looking at stocks and markets that have dropped significantly, but with an added requirement that the price has to meet a charting or technical indicator constraint before becoming a buy. While there are many who consign technical analysis to voodoo investing, I believe that charting patterns and technical indicators can provide signals of shifts in mood and momentum that drive price movements, at least in the near term. Thus, you can view technical contrarianism as buying stocks or markets when they are down, but only if the charts and technical indicators point to a shift in market mood.

    One of the problems with testing technical contrarianism, to see if it works, is that even among technical analysts, there seems to be no consensus as to the best indicator to use, but broadly speaking, these indicators can be based on either price and/or volume movements. They range in sophistication from simple measures like relative strength (where you look at percentage price changes over a period) and moving averages to complex ones that combine price and volume. In recent decades, investors have added pricing in other markets to the mix, with the VIX (a traded volatility index) as well as the relative pricing of puts and calls in the options market being used in market timing. In sum, all of these indicators are directed at measuring fear in the market, with a "market capitulation" viewed as a sign that the market has bottomed out. 

    With market timing indicators, there is research backing up the use of VIX and trading volume as predictors of market movements, though with substantial error.

Source: S&P

As the VIX rises, the expected return on stocks in future periods goes up, albeit with much higher volatility around these expected returns. It is ironic that some of the best defenses of technical analysis have been offered by academics, especially in their studies of price momentum and reversal. Lo, Wang, and Mamaysky present a fairly convincing defense of technical analysis from the perspective of financial economists. They use daily returns of stocks on the New York Stock Exchange and NASDAQ from 1962 and 1996 and employ sophisticated computational techniques (rather than human visualization) to look for pricing patterns. They find that the most common patterns in stocks are double tops and bottoms, followed by the widely used head and shoulders pattern. In other words, they find evidence that some of the most common patterns used by technical analysts exist in prices. Lest this be cause for too much celebration among chartists, they also point out that these patterns offer only marginal incremental returns (an academic code word for really small) and offer the caveat that these returns may not survive transaction costs.

3. Constrained Contrarianism

    If you are in the old-time value investing camp, your approach to contrarian investing will reflect that worldview, where you will buy stocks that have dropped in value, but only if they meet the other criteria that you have for good companies. In short, you will start with a list of beaten up stocks, and then screen them for high profitability, strong moats and low risk, hoping to separate companies that are cheap from those that deserve to be cheap.

    As a constrained contrarian, you are hoping to avoid value traps, every value investor's nightmare , where a company looks cheap on a pricing basis (low PE, low price to book) and proceeds to become even cheaper after you buy it. The evidence on whether screening helps avoid value traps comes largely from studies of the interplay between proxies of value (such as low price to book ratios) and proxies for quality, including measures for both operating/capital efficiency (margins and returns on capital) and low risk (low debt ratios and volatility). Proponents of quality screens note that while value proxies alone no longer seem to deliver excess returns, incorporating quality screens seems to preserve these excess returns.  Research Affiliates, an investment advisory service, looked at returns to pure value screens versus value plus quality screens and presents the following evidence on how screening for quality improves returns:

Research Affiliates Study

The evidence is supportive of the hypothesis that adding quality screens improves returns, and does so more for stocks that look cheap (low price to book) than for expensive stocks. That said, the evidence is underwhelming in terms of payoff, at least on an annual return basis, though the payoff is greater, if you factor in volatility and estimate Sharpe ratios (scaling annual return to volatility).
    While much of the research on quality has been built around value and small cap investing, the findings can be extrapolated to contrarian investing, with the lesson being that rather than buy the biggest losers, you should be buying the losers that pass screening tests for high profitability (high returns on equity or capital) and low risk (low debt ratios and volatility). That may provide a modicum of protection, but the problem with these screens is that they are based upon historical data and do not capture structural changes in the economy or disruption in the industry, both of which have not yet found their way into the fundamentals that are in your screens.
    To provide just an illustration of constrained contrarianism, I again returned to the universe of about 6,000 publicly traded US stocks on April 18, 2025, and after removing firms with market capitalizations less than $100 million (with the rationale that these companies will have more liquidity risk and transactions costs), I screened first for stocks that lost more than 20% of their market capitalization between March 28 and April 18, and then added three value screens:
  1. A PE ratio less than 15, putting the stock in the bottom quintile of US stocks as of December 31, 2024
  2. A dividend yield that exceeded 1%, a paltry number by historical norms, but ensuring that the company was dividend-paying in 2024, a year in which 60% of US stocks paid no dividends
  3. A net debt/EBITDA ratio of less than two, dropping it into the bottom quintile of US companies in terms of debt load
The six companies that made it through the screens are below:

I am sure that if you are a value investor, you will disagree about both the screens that I used as well as my cut offs, but you are welcome to experiment with your own screens to find bargains.

4. Opportunistic Contrarianism

    In a fourth variant of contrarian investing, you use a market meltdown as an opportunity to buy companies that you have always wanted to own but could not because they were over priced before the price drop, but look under priced after.  The best place to start an assessment of opportunistic investing is with my post on why good companies are not always good investments, with the first being determined by all of the considerations that go into separating great businesses from bad businesses, including growth and profitability, and the second by the price you have to pay to buy them. In that post, I had a picture drawing the contrast between good companies and good investments:


Put simply, most great companies are neutral or even bad investments, because the market prices them to be great. A year ago, when I valued the Mag Seven stocks, I argued that these were, for the most part, great businesses, with a combination of growth at scale, high profitability and deep moats, but that at the prices that they were trading  they were not great investments. 

I also argued that even great companies have their market travails, where for periods of time, investors lose faith in them and drive their prices down not just to value, but below. It happened to Microsoft in 2014, Apple in 2017, Nvidia in 2018, Tesla at multiple times in the last decade, and to Facebook, at the height of the Metaverse fiasco. While those corrections were caused by company-specific news stories and issues, the same process can play out, when you have significant market markdowns, as we have had over the last few weeks. 

    The process of opportunistic contrarianism starts well before a market correction, with the identification of companies that you believe are good or great businesses:

At the time that you first value them, you are likely to find them to be over valued, which will undoubtedly be frustration. You may be tempted to play with the numbers to make these companies look undervalued, but a better path is to put them  on your list of companies you would like to own, and leave them there. During a market crisis, and especially when investors are marking down the prices of everything, without discriminating between good and bad companies, you should revisit that list, with a caveat that you cannot compare the post-correction price to your pre-crisis valuation of your company. Instead, you will have to revalue the company, with adjustments to expected cash flows and risk premiums, given the crisis, and if that value exceeds the price, you should buy the stock. 

Contrarian Investing: The Psychological Tests!

    In the abstract, it is easy to understand the appeal of contrarian investing. Both behavioral and empirical research identify the existence of herd behavior in crowds, and point to tipping points where crowd wisdom becomes crowd madness. A rational decision-maker in the midst of animal spirits may feel that he or she has an advantage in this setting, and rightly so. That said, buying when the rest of the market is selling takes a mindset, a time horizon and a stronger stomach than most of us do not have.

  1. The Mindset: Investing against the market will not come easily to those who are easily swayed by peer pressure, since they will have to buy, just as other investors (the peer group) will be selling, and often in companies that the market has turned against. There are  some who march to their own drummers, willing to take a path that is different from the rest, and these are better suited to being contrarians.
  2. The Time Horizon: To be a contrarian, you don't always need a long time horizon, since corrections can sometimes happen quickly, but you have to be willing to wait for a long period, if that is what is necessary for the correction. Relatively few investors have this capacity, since it is determined as much by your circumstances (age, health and cash needs) as it is by your personality.
  3. The Stomach: Even if your buy decision is based on the best thought-through contrarian investing strategies, it is likely that in the aftermath of that decision, momentum will continue to push prices down, testing your faith. Without a strong stomach, you will capitulate, and while your decision may have been right in the long term, your investment will not reflect that success.
As you can see, the decision on whether to be a contrarian is not just one that you can make based upon the evidence and theory, but will depend on who you are as a person, and your makeup. 
    I have the luxury of a long time horizon and the luck of a strong stomach, for both food and market surprises. I am not easily swayed by peer pressure, but I am not immune from it either. I know that buying stocks in the face of market selling will not come easily, and that is the reason that I initiated limit buys on three companies that I have wanted to have in my portfolio, BYD, the Chinese electric car maker, Mercado Libre, the Latin American online retail/fintech firm, and Palantir, a company that I believe is closest to delivering on thee promise of AI products and services. The limit buy kicked in on BYD on April 7, when it briefly dipped below $80,  my limit price, and while Palantir and Mercado Libre have a way to go before they hit my price limits, the crisis is young and the order is good until canceled!

YouTube Video


Thursday, March 23, 2017

A Valeant Update: Damaged Goods or Deeply Discounted Drug Company?


Rats get a bad rap for fleeing sinking ships. After all, given that survival is the strongest evolutionary impulse and that rats are not high up in the food chain, why would they not? That idiom, unfortunately, is what came to mind as I took another look at Valeant, the vessel in my investment portfolio that most closely resembles a sinking ship. This is a stock that I had little interest in, during its glory days as the ultimate value investing play, but that I took first a look at, after its precipitous fall from grace in November 2015. While I stayed away from it then, I bought it in May 2016 after it had dropped another 60% and I found it cheap enough to add to my portfolio. I then compounded my losses when I doubled my holding in October 2016, arguing that while it was, at best, an indifferently managed company in a poor business, it was under priced at $14 . With the stock trading at less than $12 (and down to $10.50, as I write this post) and its biggest investor/promoter abandoning it, there is no way that I can avert my eyes any longer from this train wreck. So, here I go!

Valeant: A Short (and Personal) History
I won't bore you by repeating (for a third time) the story of Valeant's fall from investment grace, which happened with stunning speed in 2015, as it went from value investing favorite to untouchable, in the matter of months. My first post, from November 2015, examined the company in the aftermath of the fall, as it was touted as a contrarian bet, trading at close to $90, down more than 50% in a few months. My belief then was that the company's business model, built on acquisitions, debt and drug repricing was broken and that the company, if it became a more conventional drug business company, with low growth driven by R&D, was worth $73 per share. I revisited Valeant in April 2016, after the company had gone through a series of additional setbacks, with many of its wounds self inflicted and reflecting either accounting or management misplays. At the time, with the updated information I had and staying with my story of Valeant transitioning to a boring drug company, with less attractive margins, I estimated a value per share of $44, above the stock price of $33 at the time. I bought my first batch of shares. In the months that followed, Valeant's woes continued, both in terms of operations and stock price. After it announced a revenue drop and a decline in income in an earnings report in November 2016, the stock hit $14 and I had no choice but to revisit it, with a fresh valuation. Adjusting the valuation for the new numbers (and a more pessimistic take on how long it would take for the company to make its way back to being a conventional, R&D-driven pharmaceutical company, I valued the shares at $32.50. That may have been hopeful thinking but I added to my holdings at around $14/share.

Valeant: Updating the Numbers
Since that valuation, not much has gone well for the company and its most recent earnings report suggests that its transition back to health is still hitting roadblocks. While talk of imminent default seems to have subsided, there seems to be overwhelming pessimism on the company's operating  prospects, at least in the near term. In its most recent earnings report, Valeant reported further deterioration in key numbers:
2016 10K2015 10K% Change
Revenues$9,674.00 $10,442.00 -7.35%
Operating income or EBIT$3,105.46 $4,550.38 -31.75%
Interest expense$1,836.00 $1,563.00 17.47%
Book value of equity$3,258.00 $6,029.00 -45.96%
Book value of debt$29,852.00 $31,104.00 -4.03%
Much as I would like to believe that this decline is short term and that the stock will come back, there is now a real chance that my story for Valeant, not an optimistic and uplifting story to begin with, is now broken. The company's growth strategy of acquiring other companies, using huge amounts of debt, raising prices on "under priced" drugs and paying as little in taxes as possible were perhaps legally defensible but they were ethically questionable and may have damaged its reputation and credibility so thoroughly that it is now unable to get back to normalcy. This can explain why the company has had so much trouble not only in getting its operations back on track but also why it has been unable to pivot to being a more traditional drug company. If researchers are leery about working in your R&D department, if every price increase you try to make faces scrutiny and push back and your credibility with markets is rock bottom, making the transition will be tough to do. It can also indirectly explain why Valeant may be having trouble selling some of its most lucrative assets, as potential buyers seem wary of the corporate taint and perhaps have lingering doubts about whether they can trust Valeant's numbers.

In fact, the one silver lining that may emerge from this experience is that I now have the perfect example to illustrate why being a business entity that violates the norms of good corporate behavior (even if their actions legal) can destroy value. At least in sectors like health care, where the government is a leading customer and predatory pricing can lead to more than just public shaming, the Valeant story should be a cautionary note for others in the sector who may be embarking on similar paths.

The Ackman Effect
You may find it strange that I would spend this much time talking about Valeant without mentioning what may seem to be the big story about the stock, which is that Bill Ackman, long the company's biggest investor and cheerleader and for much of the last two years, a powerful board member, has admitted defeat, selling the shares that Pershing Square (his investment vehicle) has held in Valeant for about $11 per share, representing a staggering loss of almost 90% on his investment. The reasons for my lack of response are similar to the ones that I voiced in this post, when I remained an Apple stockholders as Carl Icahn sold Apple and Warren Buffett bought the stock in April 2016. As an investor, I have to make my own judgments on whether a stock fits in my portfolio and following others (no matter how much regard I have for them) is me-too-ism, destined for failure.  

Don't get me wrong! I think Bill Ackman, notwithstanding his Valeant setbacks, is an accomplished investor whose wins outnumber his losses and when he takes a position (long or short) in a stock, I will check it out. That said, I did not buy Valeant because Ackman owned the stock and I am not selling, just because he sold. In fact, and this may seem like a stretch, it is possible that Ackman's presence in the company and the potential veto power that he might have been exercising over big decisions may have become more of an impediment than a help as the company tries to untangle itself from its past. I am not sure how well-sourced these stories are, but there are some that suggest that it was Ackman who was the obstacle to a Salix sale last year.

Valeant: Three Outcomes
As I see it, there are three paths that Valeant can take, going forward.
1. Going Concern: To value Valeant as a going concern, I revisited my valuation from November 2016 and made its pathway to stable drug company more rocky by assuming that revenues would continue to drop 2% a year and margins will stay depressed at 2016 levels for the next 5 years and that revenue growth will stay anemic (3% a year) after that, with a moderate improvement in margins. With those changes put in and leaving the likelihood that the company will not make it at 10% (since the company has made some headway in reducing debt), the value per share that I get is $13.68. 
To illustrate the uncertainty associated with this value estimate, I ran a simulation with my estimated distributions for revenue growth, margins and cost of capital and arrived at the following distribution of values.

The simulation confirms the base case intrinsic valuation, insofar as the median value of $13.31 is close to the price at the time of the valuation ($12) but it provides more information that may or may not tilt the investment decision. There is a clear chance that the equity could go to zero (about 12%), if the value dips below the outstanding debt ($29 billion). At the same time, there is significant upside, if the company can find a way to alter its trajectory and become a boring, low growth drug company.
2. Acquisition Target: It is a sign of desperation when as an investor, your best hope is that someone else will acquire your company and pay a premium for it. I am afraid that the Valeant taint so strong and its structure so opaque and complex that very few acquirers will want to buy the entire company. I see little chance of this bailing me out.
3. Sum of its parts, liquidated: It is true that Valeant has some valuable pieces in it, with Bausch & Lomb and Salix being the biggest prices. While neither business has attracted as much attention as Valeant had hoped, there are two reasons why. The first is that Ackman, with significant losses on the stock and a seat on the board, may have exercised some veto power over any potential sales. The second is that potential buyers may be scared away by Valeant's history. One solution, now that Ackman is no longer at the company, is for Valeant to open its books to potential acquirers and sell its assets individually to the best possible buyers. Note that this liquidation value will have to exceed $29 billion, the outstanding debt, for equity investors to generate any remaining cash.

There is one other macro concern that may make Valeant's future more thorny. As a company that pays a low effective tax rate and borrows lots of money, the proposed changes to the tax law (where the marginal tax rate is likely to be reduced and the tax savings from interest expenses curbed), Valeant will probably have to pay a much higher effective tax rate going forward, one reason why I have shifted to a 30% tax rate for the future.

The Bottom Line
Let's start with the easy judgment. This was not an investment that I should have made and much as I would like to blame macro forces, the company's management and Bill Ackman for my losses, this was my mistake. I was right in my initial post in concluding that the company's old business model (of acquiring growth with borrowed money and repricing drugs) was broken but I clearly underestimated how much damage that model has done to the company's reputation and how much work it will take for it to become a boring, drug company. In fact, it is possible that the damage is so severe, the company will not be able to make the adjustments necessary to survive as a going concern. 

So, now what? I cannot reverse the consequences of my original sin (of buying Valeant at $32) in April 2017 and the secondary sin (of doubling down, when Valeant was trading at $14) by selling now. The question then becomes a simple one. Would I buy Valeant at today's price? If the answer is yes, I should hold and if the answer is no, I should fold. My intrinsic value per share has dropped to just above where the stock is trading at now, and at this stage, my judgment is that, valued as a going concern, it would be trading slightly under value. In a strange way, Bill Ackman's exit is what tipped the scales for me, since it will give Valeant's management, if they are so inclined, the capacity to make the decisions that they may have been constrained from making before. In particular, if they recognize that this may be a clear case where the company is worth more as the sum of its liquidated parts than as a going concern, there is still a chance that I could reduce my losses on this investment. Note, though, that based on my numbers, I don't expect to make my original investment (which averages out to $21/share) back. I am not happy about that but sunk costs are sunk!

As I continue to hold Valeant, I am also aware that I might be committing one of investing's biggest sins, which is an aversion to admitting mistakes by selling losers. My discounted cash flow valuations may be an after-the-fact rationalizing of something that I don't want to do, i.e., sell a big loser. To counter this, I briefly considering selling the shares and rebuying them back immediately; that makes me admit my mistake and take my losses while restarting the investment process with a new buy, but the "wash sales" rule is an impediment to this cleansing exercise. The bottom line is that if I am holding on to Valeant, not for intrinsic value reasons (as I am trying to convince myself) but because I have an investing blind spot, I will be last one to know!

YouTube Video


Previous Posts on Valeant
  1. Checkmate or Stalemate: Valeant's Fall from Investing Grace (November 2015)
  2. Valeant: Information Vacuums, Management Credibility and Investment Value (April 2016)
  3. Faith, Feedback and Fear: The Valeant Test (November 2016)
Spreadsheets
  1. Valeant Valuation: March 2017


Tuesday, November 22, 2016

Faith, Feedback and Fear: Ready for the Valeant Test?

It is easier and more fun to write about your winners than your losers, but it is also far more important and valuable to revisit your losers, where the story has not played out the way you hoped it would. It is important because it is easy to lapse into denial and hold on to your losers too long, not only because you let hope override good sense but also because the act of selling is the ultimate admission that you made a mistake. It is valuable because you can learn from these mistakes, if you can set aside pride and preconceptions. So, it is with mixed feelings that I am returning to Valeant, a stock that I bought in May at $27, contending that it was worth $44, but where the market has clearly had other ideas. 

Valeant: Revisiting the Past
I first wrote about Valeant just over a year ago, when it was entering its dark phase, surrounded by scandals, management intrigue and operating problems. At the time, the stock had completed a very quick descent from market star to problem child, with its stock price (market cap) dropping from $180 on October 1, 2015 to $80 on November 6, 2015. While there were many in the value investing community, where it had been a long time favorite, who felt that the market had over reacted, my valuation of $77 left me just short of the market price of $80 at the time. Over the next few months, things went from bad to worse on almost every dimension. The management team disintegrated, with many of the top players leaving in disgrace, and the company held back on reporting its financials because it was having trouble getting its books in order, never a good sign for investors. Testimony by its top managers in front of congressional committee shredded its corporate character and the company faced legal challenges on multiple fronts. The market, not surprisingly, punished the stock as the company lurched from one crisis to another and the stock price dropped almost 75%:

In May 2016, I revisited the company, just after it hired a new CEO (Joseph Papa) and Bill Ackman, a long-time activist investor in the company, decided to take a more active role in the company. In revaluing the company, I noted that the missteps at the company had hamstrung it to the point that it had during the period of a year made the transition from Valeant the Star to Valeant the Dog. The value that I estimated for the company, viewed as such, was $43.56.

Download spreadsheet
In keeping with my theme that the value of a company always comes from an underlying story, it is worth being explicit about the story that I was telling in this valuation. In May 2016, I viewed Valeant as a mature pharmaceutical company that would not only never be able to go back to its “acquisitive” days but was likely to lose ground to other pharmaceutical companies with better R&D models. Consequently, in my valuation, I assumed low revenue growth and lower margins and a return on capital that would converge on the cost of capital over time. My decision in May 2016 was to buy Valeant at $27 because I felt that, notwithstanding the fog of missing information, management changes and legal sanctions, the company was a good buy. 

The Market Speaks
In the months since my buy in May 2015, there has been little to cheer about for Valeant investors. The stock had an extended swoon in late June, recovered somewhat in August, before continuing its descent in the last two months, with three possible explanations for the price performance. One is that the debt overhang, with $30 billion plus in debt due, making it the most highly levered company in the pharmaceutical business, creates market spasms each time worries about default resurface. In fact, every few weeks, another rumor surfaces of Valeant planning to sell a major chunk of itself (Bausch and Lomb, Salix) to remove the debt burden. The second is that the consolidation and cleaning up for past mistakes seems to be taking a lot longer than expected, with revenues stagnating and huge impairment charges pushing equity earnings into negative territory. The third is that the legal jeopardy that was triggered by the events of last year is showing no signs of abating, with the most recent news story about indictment of Valeant executive, Gary Tanner, and Philidor's Andrew Davenport  continuing the drip-drip of bad news on this front.

For most of the last few months, as the price dropped, I have been waiting for something more concrete to emerge, so that I could revalue the company. On November 8, Valeant filed its most recent earnings report for the third quarter, reporting that revenues were down more for the third quarter of 2016 and larger losses than expected. It accompanied the report with forward guidance that suggested continued stagnation in revenues and no quick profit recovery next year, leading to a sell-off in the stock, pushing the price down to just below $14 on November 9. While I the reports is definitely not good news, I must confess that I did not see much in that report that was game or story changing. To see why, take a look at the numbers contained in the most recent earnings report:
2016, Q32015, Q3Change2016, Q1-32015, Q1-3Change
Revenues$2,480 $2,787 -11.02%$7,271 $7,689 -5.44%
COGS$658 $649 1.39%$1,946 $1,855 4.91%
S,G &A$661 $698 -5.30%$2,145 $1,957 9.61%
R&D$101 $102 -0.98%$328 $239 37.24%
Amort & Impair, finite-lived intangible assets$807 $679 18.85%$2,389 $1,630 46.56%
Goodwill Impairment$1,049 $- NA$1,049 $- NA
Acquisiton Costs (all)$67 $213 -63.93%$131 $648 -65.06%
Operating Income$(863)$448 -292.63%$(716)$1,366 -152.42%
EBIT pre-acquisition costs$(796)$661 -220.42%$(585)$2,014 -129.05%
EBITDA$1,060 $1,340 -20.90%$2,853 $3,644 -21.71%
EBITDAR$1,161 $1,442 -19.49%$3,181 $3,883 -18.08%

It is true that the company is delivering lower revenues than the revenues that I had forecast for the company in May 2016 and it is also true that the company’s profit margins are dropping. However, and this may just be my confirmation bias speaking, as I look at the third quarter numbers, it seems like a significant portion the bad news reported for the quarter reflects repentance for past sins, not fresh transgressions. The company has had to respond to its “price gouger” reputation by showing restraint on further price increases (dampening revenue growth in its drug business) and the losses in the third quarter can be largely attributed to impairments of goodwill and assets acquired during the go-go days. In the table below, I break down the drop in operating income of $2.08 billion from the first 3 quarters of 2015 to the first 3 quarters of 2016 into it's constituent parts: 
Effect on operating Income% Effect
Declining Revenues$(317)15.27%
Change in Gross Margin$(192)9.24%
Change in SG&A$(188)9.05%
Change in R&D$(89)4.29%
Change in Acquisition Costs$517 -24.89%
Change in Amortization (Assets + Goodwill)$(1,808)87.05%
Change in Operating Income, , First 3Q 2016 vs First 3Q 2015$(2,077)100.00%
The numbers suggest that almost 87% of the decline in operating income can be traced to amortization either of finite lived assets or goodwill, though there has been deterioration in the business model as manifested in the decline in sales and gross margins. It is for this reason that the effect this earnings report has had on my “Valeant as Dog” story is muted, largely because the story was not an uplifting one in the first place. My updated version of the story is that Valeant is not that different from my old one (of slow growth and lower margins) with tweaks for an upfront adjustment period where revenues are flat and margins worse than the past, as the company continues to slowly put its past behind it. The value per share that I get with this story is $32.50 and the picture is below:
On November 8, 2016, with the stock price at about $15, it was the biggest loser in my portfolio but if I trust my own updated assessment of value of Valiant, it is now more undervalued (on a percent basis) than it was in May 2016. 

Faith and Feedback
In both my valuation and investments classes, I spend a significant amount of time talking about faith and feedback and how they affect investing.
  1. Faith: As an investor, you are acting on faith when you invest, faith in your assessment of value and faith that the market price will move towards that value. If you have no faith in your value, you will find yourself constantly revisiting your valuation, if the market moves in the wrong direction (the one that you did not predict) and tweaking your numbers until your value converges on the price. If you have no faith in markets, you will not have the stomach to stay with your position if the market moves against you. 
  2. Feedback: As an investor, you have to be open to feedback, i.e., accept that your story (and valuation) are wrong and that market movements in the wrong direction are a signal that you should be revisiting your valuation. 
I view my investing challenge as maintaining a balance between faith and feedback since too much of one at the expense of the other can be dangerous. Faith without feedback can lead to doubling down or tripling down on your initial investment bet, blind to both new information and your own oversights, and that righteous pathway can lead to investment hell. Feedback without faith will cause an endless loop where market price changes lead you to revisit and change your value and your holding period will be measured in days and weeks instead of months or years.  Stocks like Valeant are an acid test of my balancing act. There is a part of me that is telling me that it is time to listen to the market, take my losses and sell the stock. However, doing that would be a direct contradiction of my investment philosophy and I am not quite ready to abandon it yet. The second is to avoid all mention of the stock and hope that the market corrects on its own, but denial is neither faith nor feedback. The third is to accept the fact that I did underestimate how long it would take Valeant to put its past behind it and to revalue the company with my updated story and that is what I tried to do. That acceptance of feedback, though, has to be accompanied by an affirmation of faith; since it led me to buy the stock at $27, when my estimated value was $43 in May 2016, it should lead me to buy even more at $15, with my estimated value at $32.50. So, I doubled my Valeant holdings, well aware of the many dangers that I face: that the operating decline that you saw in the third quarter of 2016 will continue in the future years, that the debt load will become more painful if interest rates rise and that the recent indictments of executives will expose the firm to more legal jeopardy. If the essence of risk is best captured with the Chinese symbol for crisis, which is a combination of the symbols for danger and opportunity, Valeant would be a perfect illustration of how you cannot have one without the other!

YouTube Video


Attachments

  1. Valeant - Valuation in November 2016